Skip to main content

Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.

Publication ,  Journal Article
Granville, LA; Younes, M; Churg, A; Roggli, VL; Henderson, DW; Cagle, PT
Published in: Appl Immunohistochem Mol Morphol
March 2005

Of putative specific markers for diffuse malignant mesothelioma, nuclear staining with Zymed polyclonal calretinin antibody has shown the best specificity to date for epithelial diffuse malignant mesothelioma versus adenocarcinoma. We compared specificity and sensitivity of this polyclonal antibody for diagnosis of diffuse malignant mesothelioma with a new monoclonal antibody from DAKO. One hundred eighteen adenocarcinomas and 111 diffuse malignant mesotheliomas-70 epithelial, 22 sarcomatous, and 19 biphasic-were immunostained with calretinin antibodies from Zymed (polyclonal rabbit, prediluted, PAD:DC8) and DAKO(monoclonal mouse, 1:100, clone DAK Calret 1) using manufacturer-recommended procedures. Cases were blinded and assessed for nuclear versus cytoplasmic staining, percent positive cells, and background. Both antibodies showed similar positive predictive values for diffuse malignant mesothelioma by nuclear staining (Zymed=95%; DAKO=97%). False positives in 4 (3.4%) and 2 (1.7%) adenocarcinomas, respectively, stained greater than 10% of cells. Sensitivity for epithelial malignant mesothelioma was slightly less for DAKO antibody (Zymed=80%; DAKO=73%). Neither antibody performed well on sarcomatous malignant mesothelioma (Zymed=2/22; DAKO=1/22). Both antibodies are useful in the diagnosis of epithelial malignant mesothelioma, although monoclonal antibody is slightly less sensitive.

Duke Scholars

Published In

Appl Immunohistochem Mol Morphol

DOI

ISSN

1541-2016

Publication Date

March 2005

Volume

13

Issue

1

Start / End Page

75 / 79

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • S100 Calcium Binding Protein G
  • Predictive Value of Tests
  • Pleural Neoplasms
  • Pathology
  • Mesothelioma
  • Immunohistochemistry
  • Humans
  • Calbindin 2
  • Biomarkers, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Granville, L. A., Younes, M., Churg, A., Roggli, V. L., Henderson, D. W., & Cagle, P. T. (2005). Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol, 13(1), 75–79. https://doi.org/10.1097/00129039-200503000-00012
Granville, Laura A., Mamoun Younes, Andrew Churg, Victor L. Roggli, Douglas W. Henderson, and Philip T. Cagle. “Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.Appl Immunohistochem Mol Morphol 13, no. 1 (March 2005): 75–79. https://doi.org/10.1097/00129039-200503000-00012.
Granville LA, Younes M, Churg A, Roggli VL, Henderson DW, Cagle PT. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75–9.
Granville, Laura A., et al. “Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.Appl Immunohistochem Mol Morphol, vol. 13, no. 1, Mar. 2005, pp. 75–79. Pubmed, doi:10.1097/00129039-200503000-00012.
Granville LA, Younes M, Churg A, Roggli VL, Henderson DW, Cagle PT. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75–79.

Published In

Appl Immunohistochem Mol Morphol

DOI

ISSN

1541-2016

Publication Date

March 2005

Volume

13

Issue

1

Start / End Page

75 / 79

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • S100 Calcium Binding Protein G
  • Predictive Value of Tests
  • Pleural Neoplasms
  • Pathology
  • Mesothelioma
  • Immunohistochemistry
  • Humans
  • Calbindin 2
  • Biomarkers, Tumor